Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 selpercatinib versus cabozantinib or vandetanib in RET-mutant medullary thyroid cancer
NL-OMON60317Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selpercatinib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival by blinded independent central review. Started Mar 2021; status: completed.
02
Drugs
selpercatinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON60317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60317.